Vimizim 2015 U.S. PROMOTIONAL AUDIT REPORT

Published July 2016 • 25 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Vimizim through personal promotion in 2015 to drive use within the Mucopolysaccharidosis Type IV market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does BioMarin’s depth of coverage vary within key specialties (e.g., Medical Genetics, Neurology, Pediatric Medicine, Orthopedic Surgery, and Internal Medicine) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Vimizim throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Vimizim in 2015?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 300 paid interactions across 100 physicians made on behalf of Vimizim were carefully examined to support our analysis.